Copertina

Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	You Cheng, Adrián Medina, Cole Korponay, Christian F. Beckmann, David Harper, Lisa Nickerson
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
di: Seyed Hani Hojjati, et al.
Pubblicazione: (2025)

Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
di: Soheil Mohammadi, et al.
Pubblicazione: (2025)

White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
di: Antoine Garnier‐Crussard, et al.
Pubblicazione: (2026)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
di: Cassandra Marotta, et al.
Pubblicazione: (2025)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
di: Hossein Moein Taghavi, et al.
Pubblicazione: (2024)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
di: Caitlin M. Terao, et al.
Pubblicazione: (2025)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
di: Lara Blömeke, et al.
Pubblicazione: (2024)

Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer's disease staging
di: Ann M. Stowe, et al.
Pubblicazione: (2026)

Midlife sensory and motor functions improve prediction of blood‐based measures of neurodegeneration and Alzheimer's disease in late middle‐age
di: Adam J. Paulsen, et al.
Pubblicazione: (2024)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
di: Yury Loika, et al.
Pubblicazione: (2024)

Correction to “Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology”
Pubblicazione: (2024)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
di: Miguel Ángel Rivas‐Fernández, et al.
Pubblicazione: (2026)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
di: Giorgia Brodini, et al.
Pubblicazione: (2026)

Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
di: Annibale Antonioni, et al.
Pubblicazione: (2025)

Prevalence of cerebral amyloid angiopathy and its correlation with Alzheimer's disease and cognition in an autopsy‐confirmed cohort from China
di: Xiang‐Sha Yin, et al.
Pubblicazione: (2025)

Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden
di: Aubrey S Johnson, et al.
Pubblicazione: (2026)

Body composition and plasma total‐tau, neurofilament light chain, and amyloid‐β: A population‐based study
di: Tosca O. E. de Crom, et al.
Pubblicazione: (2024)

Inner and outer retinal abnormalities detected in Alzheimer's disease subjects diagnosed by amyloid PET not revealed when classified based on clinical criteria
di: Leonardo E. Ariello, et al.
Pubblicazione: (2025)

Diagnostic value of fluid‐based non‐amyloid biomarkers for Alzheimer's disease and related dementias in a clinic‐based cohort from South Asia
di: Faheem Arshad, et al.
Pubblicazione: (2025)

Novel insights into early Alzheimer's disease: quantitative gradient recalled echo MRI reveals preatrophic neuronal and myelin injury concurrent with emerging amyloid pathology
di: Satya V. V. N. Kothapalli, et al.
Pubblicazione: (2026)

Investigating the relationship between sleep disturbances and white matter hyperintensities in older adults on the Alzheimer's disease spectrum
di: Farooq Kamal, et al.
Pubblicazione: (2024)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
di: Sayo Matsuura, et al.
Pubblicazione: (2026)

The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome
di: Julianne G. Clina, et al.
Pubblicazione: (2026)

Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
di: Kazuki Yamada, et al.
Pubblicazione: (2026)

An online vignette study of diagnostic testing: Racial and ethnic differences in Alzheimer's disease diagnosis confidence and stigma
di: Shana D. Stites, et al.
Pubblicazione: (2025)

Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
di: María A. Rodríguez‐Santiago, et al.
Pubblicazione: (2024)

Characterizing Japanese older adults without dementia by amyloid PET status: A comparative study of amyloid‐positive and amyloid‐negative groups from Japanese trial‐ready cohort study
di: Saki Nakashima, et al.
Pubblicazione: (2026)

Association between BrainAGE and Alzheimer's disease biomarkers
di: Yousaf Abughofah, et al.
Pubblicazione: (2025)

General practitioners’ perspectives on blood biomarkers for Alzheimer's disease
di: Thomas Claessen, et al.
Pubblicazione: (2025)

Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
di: Diana Esteller‐Gauxax, et al.
Pubblicazione: (2026)

Treating Alzheimer's disease in a person living with HIV
di: David B. Clifford, et al.
Pubblicazione: (2026)

Interchangeability of CSF and PET to identify Alzheimer's disease pathology
di: Samantha C. Burnham, et al.
Pubblicazione: (2026)

Diagnostic performance of light reflex pupillometry in Alzheimer's disease
di: Mathias Holsey Gramkow, et al.
Pubblicazione: (2024)

Plasma amyloid‐β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort
di: Yuhan Xie, et al.
Pubblicazione: (2025)

Intracranial arteriosclerosis is not associated with cerebral amyloid deposition
di: Anna M. Streiber, et al.
Pubblicazione: (2024)

Cerebrospinal fluid sclerostin levels in the early Alzheimer's disease stages
di: Manuela Dicarlo, et al.
Pubblicazione: (2026)

Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease
di: Peter Thomas, et al.
Pubblicazione: (2024)

Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints
di: Alisa Bannerjee, et al.
Pubblicazione: (2025)

Longitudinal changes in functional capacity in frontotemporal dementia and Alzheimer's disease
di: David Foxe, et al.
Pubblicazione: (2024)

Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
di: Sofia Toniolo, et al.
Pubblicazione: (2024)